KIORA PHARMACEUTICALS INC
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
Business Address
169 SAXONY RD., ENCINITAS, CA, 92024
Mailing Address
169 SAXONY RD., ENCINITAS, CA, 92024
Phone
858-224-9600
Fiscal Year End
1231
EIN
980443284
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 7, 2026 | View on SEC |
| 8-K Current report of material events | April 2, 2026 | View on SEC |
| 4 Insider stock transaction report | April 2, 2026 | View on SEC |
| 4 Insider stock transaction report | April 2, 2026 | View on SEC |
| 4 Insider stock transaction report | April 2, 2026 | View on SEC |
| 8-K Current report of material events | March 25, 2026 | View on SEC |
| 10-K Annual financial report | March 25, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
Annual Reports
10-K
March 25, 2026
- KIO-301 received Orphan Drug Designation, providing 7 years of market exclusivity and significant cost savings.
- Strategic partnership with Thea Open Innovation (TOI) provides non-dilutive funding and European commercialization pathways.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.